期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

血管抑素基因联合^(32)P-胶体治疗大鼠肝癌的疗效 被引量：3

下载PDF
导出
摘要 目的评价血管抑素基因联合放射性药物32P胶-体治疗肝癌的疗效。方法大鼠分为三组:血管抑素基因治疗(治疗)组,血管抑素基因+32P-胶体联合治疗(联合)组,空白对照组,每组20只。观察肿瘤体积、肿瘤微血管密度(MVD)、肿瘤细胞凋亡指数(AI)的变化。结果 RT-PCR结果显示,在治疗组和联合组的大鼠肿瘤内,可见到大小为1 400 bp的血管抑素mRNA特异性表达条带;而对照组未见到血管抑素mRNA表达;治疗组和联合组不同时间的肿瘤生长率均小于对照组(P<0.01)。联合组肿瘤生长率最小,MVD最低,提示多种具有协同作用的因素相互作用后抑瘤效果最好。结论血管抑素和放射性药物32P胶-体通过抑制肿瘤血管内皮细胞增殖及迁移达到抑瘤的目的,具有很好的抗肝癌疗效。
作者 马铎 于峰 高慧棋 孟昕 杨志杰 李勇
机构地区 哈尔滨医科大学附属第一医院PET-CT室
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第21期4202-4204,共3页 Chinese Journal of Gerontology
关键词 血管抑素 基因 32P-胶体 肝癌
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

二级参考文献10

  • 1MerrittRE,YamadaRE,CrystalRG, etal.Augmentingmajorhisto compatibilitycomplexclassⅠexpressionbymurinetumorsinvivoenhancesantitumorimmunityinducedbyanactiveimmunotherapystrategy[].Journal of Thoracic and Cardiovascular Surgery.2004
  • 2XiangJ,MoyanaT.CytotoxicCD4+TcellsassociatedwiththeexpressionofmajorhistocompatibilitycomplexclassⅡantigenofmousemyelomacellssecretinginterferon gammaarecytolyticinvitroandtumoricidalinvivo[].CancerGeneTher.1998
  • 3VanDerVeldenAW,ThomasAA.Theroleofthe5’untranslatedregionofanmRNAintranslationregulationduringdevelopment[].IntJBiochemCellBiol.1999
  • 4Weichselbaum RR,Kufe DW,Hellman S,et al.Radiation-induced tumour necrosis factor-αexpression:clinical application of transcriptional and physical targeting of gene therapy[].The Lancet Oncology.2002
  • 5Marples B,Greco O,Joiner MC,et al.Radiogenetic therapy:Strategies to overcome tumor resistance[].Current Pharmaceutical Design.2003
  • 6Weichselbaum RR,Kufe DW,Advani SJ,et al.Molecular targeting of gene therapy and radiotherapy[].Acta Oncologica.2001
  • 7Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors[].Breast Cancer Research.1995
  • 8O’Relly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[].Cell.1997
  • 9Qin Z,Schwartzkopff J,Pradera F,et al.A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells[].Cancer Research.2003
  • 10Hayakawa Y,Takeda K,Yagita H,et al.IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alphagalactosylceramide[].Blood.2002

共引文献19

同被引文献26

  • 1张兴德,郁红礼,周玲玲,刘汉清.正交法筛选莪术油微球制备工艺[J].南京中医药大学学报,2007,23(5):304-306. 被引量：11
  • 2Kassis AI, Adelstein SJ. Radiobiologic principles in radionucl idether- apy[J]. J Nucl Med, 2005, 46( 1 ): 4-12.
  • 3Kosaka N, Ogawa M, Choyke PL, et al. In vivo stable tumor specif-ic painting in various colors using dehalogenase based protein-tag fluore- scent ligands[J]. Bioconjug Chem, 2009, 20 (6): 1367-1374.
  • 4Harris AL. Hypoxia-a key regulatory factor in tumor growth [J]. NatRev Cancer, 2002, 2(1 ): 38-47.
  • 5Ballinger JR. Imaging hypoxia in tumors [J]. Sem in Nucl Med,2001, 31 : 321-329.
  • 6Imathashi K, Morishita K, Kusuoka H. Kinetics of a putative hypo-xic tracer, 99Tcm-HL91, in normoxic, hypoxic, ischemic, and stunned my- oca-rdium[J]. J Nucl Med, 2000, 41 : 1102-1107.
  • 7Brown JM, Giaccia AJ. The unique physiology of solid tumors: oppo- tunit-tumors:opportunities(and problems)for cancer therapy[J]. Cancer Res, 1998, 58:1408-1416.
  • 8Suzuki T, Nakamura K, Kawase T, et al. Biodistribution of hypoxic maker, 99Tcm-HL91 (4,9-diaza-3, 3, 10, 10-tetramethyldodecan-2,11 -dione dioxime)[J]. Kaku lgaku, 2001, 38:333-341.
  • 9Zhang X, Melo T, Ballinger JR, et al. Studies of99mTcBnAO(HL91) : a non-nitroaromatic compound for hypoxic cell diction [J]. Int J Radiat Oncol Biol Phys, 1998, 42:737-740.
  • 10SiimBG, Laux WT, Rutland MD, et al. Scintigraphic imaging of theh- ypoxia marker 99mTc labeled 2, 2' (1,4-diaminobutane) his (2-methyl -3-butanone) dioxime (99mTc-labeled HL-91 ;prog-nox): noninvasive detection of tumor response to the antivascular a-gent 5,6-dimethylx- anthenone-4-acetie acid[J]. Cancer Res, 2000, 60:4582-4588.

引证文献3

二级引证文献5

中国老年学杂志
2011年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部